FMP
BioAtla, Inc.
BCAB
NASDAQ
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
2.25 USD
-0.1 (-4.44%)
About
ceo
Dr. Jay M. Short Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.bioatla.com
exchange
NASDAQ
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical ...
CIK
0001826892
ISIN
US09077B1044
CUSIP
09077B104
Address
11085 Torreyana Road
Phone
858 558 0708
Country
US
Employee
65
IPO Date
Dec 16, 2020
Summary
CIK
0001826892
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
09077B104
ISIN
US09077B1044
Country
US
Price
2.25
Beta
1.06
Volume Avg.
545.69k
Market Cap
108.22M
Shares
-
52-Week
1.24-4.068
DCF
2.28
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.87
P/B
-
Website
https://www.bioatla.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest BCAB News
It looks like there's no news available.
